Dr. Koren joins Kevin Geddings to report live from the American Heart Association meeting in New Orleans with fresh results on LDL lowering, prevention, and the future of gene editing for cholesterol. They discuss the excitement of big meetings like the AHA and how results can even surprise the investigators that were working on a study.
Note: Dr. Koren refers to CRISPR Therapeutics, a company developing gene-based cholesterol lowering technologies. CRISPR-Cas9 is also the general name of a gene editing technique.
Be a part of advancing science by participating in clinical research.
Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.com
Listen on Spotify
Listen on Apple Podcasts
Watch on YouTube
Share with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.
Follow us on Social Media:
Facebook
Instagram
X (Formerly Twitter)
LinkedIn
Want to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.com
Music: Storyblocks - Corporate Inspired
Thank you for listening!
